Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$14.16 +1.49%

+$0.37 today

Market cap
$1.25B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.17M

Average 1.48M

Balance Sheet

Inspect the capital base behind the business.

Assets

$661.81M

FY 2025 · Annual

+221.4% YoY

Liabilities

$15.11M

FY 2025 · Annual

+3.2% YoY

Equity

$646.69M

FY 2025 · Annual

+238.1% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.61M87.7M49.3M114.09M172.92M
Short-term Investments022.41M187.26M84.1M483.71M
Net Receivables00000
Inventory00000
Other Current Assets50K2.7M12.54M7.16M4.75M
Total Current Assets11.12M112.81M249.1M205.35M661.39M
Property, Plant & Equipment (Net)00053K38K
Goodwill00000
Intangible Assets00000
Long-term Investments002.48M00
Tax Assets00000
Other Non-current Assets3K1.63M51K499K382K
Total Non-current Assets3K1.63M2.53M552K420K
Total Assets11.13M114.44M251.64M205.9M661.81M
Account Payables763K1.91M601K479K2.02M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities313K665K1.6M3.58M7.56M
Total Current Liabilities5.05M8.07M10.48M14.65M15.11M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities29M158.64M000
Total Non-current Liabilities29M158.64M000
Total Liabilities34.05M166.71M10.48M14.65M15.11M
Common Stock1K1K4K5K8K
Retained Earnings(23.01M)(52.81M)(124.71M)(302.52M)(457.17M)
Accumulated OCI00(251.64M)00
Other Stockholders Equity(29M)0000
Minority Interest00000
Total Equity(22.93M)(52.27M)241.15M191.26M646.69M
Total Debt00000
Net Debt(10.61M)(87.7M)(49.3M)(114.09M)(172.92M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$138.3M
Short-term Investments$523.1M
Other Current$4.4M
Total Current Assets$665.8M
PP&E (Net)$27.0K
Other Non-current$2.0M
Total Non-current Assets$2.1M
Total Assets$667.9M

Analysis

Selected assets total $667.9M for Latest. The largest visible component is Short-term Investments at $523.1M, about 78.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportOct 29, 2026
4Statement of changes in beneficial ownershipOct 20, 2026
4Statement of changes in beneficial ownershipOct 20, 2026

How much cash does MLYS have?

Mineralys Therapeutics, Inc. (MLYS) reported $172.92M in cash and equivalents in fiscal 2025.

How much debt does MLYS carry?

Mineralys Therapeutics, Inc. (MLYS) reported $0.00 of total debt, with net debt of -$172.92M.